GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY20 results · Apr–Jun 2019
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹787.97 crore and net profit of ₹113.54 crore for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 787.97 | — | — | 0.00 | — |
| Other income | 30.81 | — | — | 0.00 | — |
| Total income | 818.78 | — | — | 0.00 | — |
| Profit before tax | 176.11 | — | — | 0.00 | — |
| Net profit for the period | 113.54 | — | — | 0.00 | — |
| EPS, basic (₹) | 6.70 | — | — | 0.00 | — |
| Net margin (%) | 14.4 | — | — |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 788.02 | 735.65 | +7.1% | 751.22 | +4.9% |
| Other income | 30.54 | 17.78 | +71.8% | 52.46 | −41.8% |
| Total income | 818.56 | 753.43 | +8.6% | 803.68 | +1.9% |
| Profit before tax | 176.03 | 138.31 | +27.3% | 199.16 | −11.6% |
| Net profit for the period | 113.46 | 88.59 | +28.1% | 123.03 | −7.8% |
| EPS, basic (₹) | 6.70 | 10.46 | not comparable | 7.26 | −7.7% |
| Net margin (%) | 14.4 | 12.0 | 16.4 |
Consolidated
- Filed with BSE
- 23 Jul 2019, 12:24 IST
- Board meeting
- 22 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Jul 2019, 12:24 IST
- Board meeting
- 22 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE